Pharmala Biotech Holdings Inc

Pharmala Biotech Holdings Inc (PHLM) is a tiny Canadian biotech focused on oncology, trading at CAD 0.10 with a CAD 12 m market cap and a negative P/E—an overview of its precarious finances and high‑risk investment profile for speculative traders.

Pharmala Biotech’s oncology‑focused R&D and commercial partnerships are driving breakthrough cancer therapies, boosting investor confidence despite a low stock price.

Pharmala Biotech Holdings: oncology‑focused Canadian biotech with strong R&D and partnership plans, yet facing cash‑burn and volatility; investors weigh potential breakthroughs versus financial risk.

Pharmala Biotech Holdings Inc., a Canadian biotechnology firm, is making significant strides in the biopharmaceutical industry through its innovative therapeutic agents and strategic partnerships, positioning it for future growth and success in the …

Pharmala Biotech Holdings Inc. has incorporated a new Australian entity, PharmAla Biotech Australia Pty Ltd., to bolster its clinical research capabilities and accelerate the development of its proprietary therapeutic agents, particularly in the fie…

Pharmala Biotech Holdings Inc. is a Canadian biotech company pioneering innovative cancer therapies through its robust research and development efforts, strategic partnerships, and commitment to delivering transformative patient outcomes.